DUBLIN--(BUSINESS WIRE)--The "Gene Editing beyond CRISPR Market: Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies: Distribution by Type of Payment and Distribution by Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the ZFNs, TALENs and meganucleases based therapies market, in the mid to long term. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
Companies Mentioned
- Adage Capital Management
- Agent Capital
- Alexandria Venture Investments
- Allogene Therapeutics
- Amgen Ventures
- ArrowMark Partners
- Baxter Ventures
- BellCo Capital
- Biogen
- Bioverativ (part of Sanofi)
- bluebird bio
- Brace Pharma Capital
- California Institute for Regenerative Medicine
- Cellectis
- City of Hope National Medical Center
- Cormorant Asset Management
- Cowen Healthcare Investments
- Cytovia Therapeutics
- Deerfield Management
- Ditch Plains Capital Management
- Dow AgroSciences
- DSAM Partners
- DUMAC
- Edmond de Rothschild
- Eli Lilly and Company
- Eurazeo
- Fidelity Management and Research Company
- Fox Chase Cancer Center
- F-Prime Capital
- Franklin Templeton Investments
- And Many More Companies!
Isolation of the first site-specific restriction enzyme, Hind II, in the 1970s, became one of the breakthrough advances in biotechnology. This led to the discovery of various methods for manipulating living creatures at the genomic level, thereby, opening up a slew of new possibilities in basic and applied life sciences domain. Soon after, in the 1980s, the US FDA authorized human insulin, marketed under the brand name HUMULIN, as the world's first genetically modified medication.
With the development of various DNA modulation technologies, such as zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short palindromic repeats (CRISPR), genetic engineering and genome editing concepts have gained significant attention over the last two decades. In fact, there have been several advancements in the field of genome editing, which provide investigators the ability to introduce sequence-specific modifications into the genomes of a broad spectrum of cell types and organisms.
Several medical researchers and industry stakeholders are presently engaged in exploring the potential of different gene editing technologies for basic research and development of gene editing solutions. However, the therapeutic use of these versatile genetic manipulation tools is only being investigated by selective stakeholders in the pharmaceutical and biotechnology sector. This can be attributed to the implementation of surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to the drug developers.
Clinical trials of ZFNs, TALENs and meganuclease based therapeutics are primarily focused on infectious diseases and oncological disorders; however, several product candidates against certain hematological disorders, genetic disorders and neurological disorders are being evaluated in discovery and preclinical stages of development. Over time, a number of industry and non-industry players have also been validating the therapeutic applications of these technologies, which has, in turn, prompted the establishment of strategic partnerships.
In fact, the growing popularity of such technologies has attracted an investment worth USD 2 billion into companies engaged in this field of research. Promising clinical results, and ongoing technical developments, coupled with the growing interest of biopharmaceutical developers, are anticipated to push the pipeline products to higher phases of development. We believe that the market is likely to evolve at a sustained pace over the next decade.
Key Questions Answered
- Who are the players engaged in the development of gene editing therapies beyond CRISPR?
- Which are the key drugs being developed across early and late stages of development?
- Which companies are actively involved in conducting clinical trials for ZFNs, TALENs and meganucleases based therapies?
- What is the focus of various publications related to ZFNs, TALENs and meganucleases based therapies?
- Which are the leading administering institute centers supporting the research related to gene editing market beyond CRISPR?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What is the trend of capital investments in the gene editing beyond CRISPR market?
- How has the intellectual property landscape in this market evolved over the years?
- How is the current and future opportunity, related to ZFNs, TALENs and meganucleases based therapies, likely to be distributed across key market segments?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. ZFNS, TALENS AND MEGANUCLEASES BASED THERAPEUTICS: MARKET LANDSCAPE
5. COMPANY PROFILES
6. CLINICAL TRIALS ANALYSIS
7. PUBLICATION ANALYSIS
8. ACADEMIC GRANTS ANALYSIS
9. PARTNERSHIPS AND COLLABORATIONS
10. FUNDING AND INVESTMENT ANALYSIS
11. PATENT ANALYSIS
12. KEY INSIGHTS ON KOLs
13. CASE STUDY: CRISPR / CAS BASED THERAPEUTICS
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
15. APPENDIX 1: LIST OF FIGURES AND TABLES
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/yie6or
